Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb and Pharmasset have collaborated to evaluate the utility of Bristol-Myers Squibb’s NS5A replication complex inhibitor BMS-790052, in combination with Pharmasset’s nucleotide polymerase inhibitor PSI-7977, for the treatment of chronic hepatitis C virus (HCV).
Subscribe to our email newsletter
The proof of concept study will evaluate the potential to achieve sustained viral response 24 weeks post treatment with an oral, once-daily treatment regimen in patients across HCV genotypes.
Specifically, the study will assess the safety, pharmacokinetics and pharmacodynamics of BMS-790052 in combination with PSI-7977, with and without ribavirin, in treatment-naïve patients chronically infected with HCV genotypes 1, 2, and 3.
Pharmasset chief medical officer Michelle Berrey said the collaboration represents one of many approaches they are pursuing with their portfolio of nucleoside/tide analogs that include both interferon free and interferon sparing regimens.
"We believe the development of an all oral treatment regimen represents an important evolution in the treatment of HCV," Berrey said.